News AnGes, Inc.

Equities

4563

JP3127700007

Market Closed - Japan Exchange Other stock markets 11:30:00 07/05/2024 am IST			5-day change	1st Jan Change
49 ^JPY	0.00%		0.00%	-31.94%

19/01	Eiger BioPharmaceuticals Gets Marketing Approval for Treatment of Ultra-Rare Genetic Disease	MT
18/01	Eiger BioPharmaceuticals, Inc. and Partner, AnGes, Inc. Receive Approval for Zokinvy for Hutchinson- Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies in Japan	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

AnGes : Notice on the NHI Drug Price Standard Listing and Launch Schedule of Zokinvy for the Treatment of Progeria	17/04	PU
AnGes : Notice Regarding Eiger BioPharmaceuticals, Inc.	12/04	PU
AnGes : Notice of Business Restructuring at Consolidated Subsidiary	15/03	PU
AnGes : Notice of Conclusion of License Agreement and Revision of Consolidated Financial Results Forecast for FY2024	14/03	PU
Eiger and Partner, AnGes, Receive Approval for Zokinvy for Hutchinson- Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies in Japan	19/01	AQ
Eiger BioPharmaceuticals Gets Marketing Approval for Treatment of Ultra-Rare Genetic Disease	19/01	MT
Eiger BioPharmaceuticals, Inc. and Partner, AnGes, Inc. Receive Approval for Zokinvy for Hutchinson- Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies in Japan	19/01	CI
Vasomune Therapeutics, Inc. and AnGes Announce Drug Candidate AV-001 Receives Positive Recommendation from the IDSMB for AV001-004 Phase 2a Study	14/11	CI
AnGes : Consolidated Financial Report for the Third Quater 2023	08/11	PU
AnGes : Notice Regarding the Start of Administration of NF-κB Decoy Oligo DNA for the Treatment of Chronic Intervertebral Disc Lumbago in a Phase II Clinical Trial in Japan	18/23/18	PU
AnGes : Consolidated Financial Report Q2 2023	09/23/09	PU
AnGes : Consolidated Financial Report for the Second Quater 2023	09/23/09	PU
Tupperware Brands Corporation : Plastic is fantastic	08/23/08
AnGes : Clinical Research Laboratory has now established "Genetic Testing" technology and aims to begin accepting orders for "genetic testing" in winter 2023	24/23/24	PU
AnGes : Begin contracted expanded newborn screening from municipalities and related institutions from April 2024 at AnGes Clinical Research Laboratory	18/23/18	PU
AnGes : Begin contracted expanded newborn screening from municipalities and related institutions from April 2024 on AnGes Clinical Research Laboratory	18/23/18	PU
AnGes, Inc. announced that it has received Â¥8.481467 million in funding	12/23/12	CI
AnGes, Inc. announced that it expects to receive Â¥8.481467 million in funding	26/23/26	CI
AnGes : filed for approval of its HGF gene therapy product Collategene® for the first time since the introduction of the conditional/time-limited authorization system for regenerative medicine products	31/23/31	PU
Forex: A dead cat bounce?	15/23/15

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News AnGes, Inc.

Equities

4563

JP3127700007

Summary

Filters